Autologous Hematopoietic Stem Cell Infusion for Prolonged Cytopenia After CAR-T Cell Therapy (ICAHT-001)
A Prospective, Single-Arm, Single-Center Study of Autologous Hematopoietic Stem Cell Infusion for Prolonged Cytopenia After CAR-T Cell Therapy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Gang An, PhD&MD
- Phone Number: 86-022-23909171
- Email: angang@ihcams.ac.cn
Study Locations
-
-
Tianjin
-
Tianjin, Tianjin, China
- Recruiting
- Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences
-
Contact:
- Gang An
- Phone Number: 86-022-23909171
- Email: angang@ihcams.ac.cn
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Ability to understand and willingness to sign a written informed consent form (ICF).
- Age ≥ 18 years.
- Diagnosis of multiple myeloma according to the International Myeloma Working Group (IMWG) criteria.
- Prior treatment with CAR-T cell therapy and currently in remission or, in the opinion of the investigator, with refractory/progressive disease not requiring salvage therapy.
- Presence of grade 3-4 cytopenia (absolute neutrophil count < 1.0 × 10⁹/L, or platelet count < 50 × 10⁹/L, or hemoglobin < 80 g/L) either persisting or newly developed between day 30 and day 90 after CAR-T cell infusion; or deemed suitable for inclusion by the investigator based on clinical judgment.
- Availability of ≥ 1 × 10⁶/kg autologous hematopoietic stem cells in reserve.
Exclusion Criteria:
- Known intolerance, hypersensitivity, or contraindication to autologous hematopoietic stem cell infusion.
- Active hepatitis B or hepatitis C virus infection.
- Known HIV infection.
- Life expectancy <6 months.
- Woman who are pregnant or breastfeeding.
- Evidence of uncontrolled dysfunction of heart, lung, brain, and other important organs.
- Any other conditions that are not eligible for the trial in the judgement of the principal investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Autologous hematopoietic stem cell infusion
|
Autologous hematopoietic stem cell infusion (0.5-3.0×10^6/kg)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in Neutrophil Counts After Autologous Stem Cell Infusion
Time Frame: up to 6 months after infusion
|
Evaluate changes in neutrophil counts following autologous hematopoietic stem cell infusion.
|
up to 6 months after infusion
|
|
Changes in Platelet Counts After Autologous Stem Cell Infusion
Time Frame: up to 6 months after infusion
|
Evaluate changes in platelet counts following autologous hematopoietic stem cell infusion.
|
up to 6 months after infusion
|
|
Changes in Hemoglobin Levels After Autologous Stem Cell Infusion
Time Frame: up to 6 months after infusion
|
Evaluate changes in hemoglobin levels following autologous hematopoietic stem cell infusion.
|
up to 6 months after infusion
|
|
Incidence and Severity of Adverse Events Following Autologous Stem Cell Infusion
Time Frame: up to 6 months after infusion
|
Assess safety by monitoring infusion-related adverse events, graded according to CTCAE v5.0.
|
up to 6 months after infusion
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of Infections After Autologous Stem Cell Infusion
Time Frame: up to 6 months after infusion
|
Evaluate the frequency and types of infections following stem cell infusion, including bacterial, viral, and fungal infections.
|
up to 6 months after infusion
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IIT2025001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.